权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nitric Oxide and Bone Homeostasis in Patients with Argininosuccinate Lyase Deficiency

精氨基琥珀酸裂解酶缺乏症患者的一氧化氮和骨稳态

基本信息

批准号：
9896758
负责人：
Brendan Lee
金额：
$ 41.84万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9896758
关键词：
Address Affect Ammonia Ancillary Study Architecture Arginine Argininosuccinate lyase deficiency Biology Bone Diseases Cardiovascular Diseases Caveolins Cell Lineage Cell model Cells Citrulline Clinical Research Coculture Techniques Complex Coupling Data Defect Dietary Nitrite Disease Dual-Energy X-Ray Absorptiometry Enteral Enzymes Equilibrium Exhibits Fibroblasts Fostering Genetic Genetic Diseases Genetic Models Genotype Goals Heat-Shock Proteins 90 Homeostasis Human Human Genetics Hyperammonemia Hypertension In Vitro Individual Intellectual functioning disability Intervention Trial Isotopes Knock-out Modeling Mus Natural History Nitric Oxide Nitric Oxide Synthase Nitrite Reductase Nitrites Osteoblasts Osteocalcin Osteoclasts Osteoporosis Outcome Pathway interactions Patients Peripheral Pharmacology Phenotype Physiological Processes Placebos Process Production Protein Isoforms Randomized Rare Diseases Reaction Recycling Regulation Role Salivary Secondary to Signal Transduction Signaling Molecule Site Source Structure Supplementation TNFSF11 gene Therapeutic Therapeutic Intervention Therapeutic Studies Transgenic Organisms United States National Institutes of Health Urea Urea cycle disorders argininosuccinate lyase argininosuccinate synthase base bone bone mass bone metabolism bone turnover density design dietary nitrate enzyme substrate extracellular human model in vivo induced pluripotent stem cell insight mouse genetics neurocognitive test osteoblast differentiation osteoclastogenesis primary endpoint rare genetic disorder response secondary endpoint tool translational study treatment effect urea cycle

项目摘要

Project Summary Nitric oxide (NO), a ubiquitous signaling molecule, is important for most physiological processes including bone homeostasis. However, extensive in vitro and in vivo studies that have assessed the role of NO in bone biology have often yielded contrasting results. This is at least in part due to the fact that pharmacologic inhibition of nitric oxide synthases (NOS) or genetic models of NOS deficiency are limited by the redundancies of the NOS isoforms and cannot address the cell- autonomous roles of NO. Argininosuccinate lyase (ASL), is a urea cycle enzyme is not only required for the de novo synthesis of arginine, the substrate for NOS, but also to maintain the structural integrity of a NO-synthesis complex containing NOS, argininosuccinate synthase (ASS1), the arginine transporter CAT-1, and HSP90. Loss of ASL leads to non-redundant and cell-autonomous loss of NOS-dependent NO production and thus ASL deficiency (ASLD) is a human genetic disorder of NO production. The overall goals of this proposal are to study the role of NO in bone turnover, density, and architecture in a human model of NO deficiency and to understand the mechanistic basis by which NO affects bone metabolism. By leveraging an ongoing trial in this rare genetic disorder, we will address these specific questions: 1) Do patients with ASLD have abnormalities in bone turnover and bone mass and does NOS-independent NO supplementation affect these endpoints? 2) Do patient- derived induced pluripotent stem cells (iPSC) show differentiation defects along the osteoblastic lineage and how does this impact osteoclastic differentiation? 3) Do osteoblasts derived from patient- iPSC exhibit dysregulation of NO production due to dominance of a caveolin-dependent negative regulatory NOS complex? These studies could have a significant impact on the basic understanding of bone biology and foster translational studies in utilizing NOS-independent NO supplementation as a therapeutic intervention in the more common disorders like osteoporosis.

项目概要一氧化氮 (NO) 是一种普遍存在的信号分子，对于大多数生理学都很重要过程，包括骨稳态。然而，广泛的体外和体内研究表明评估 NO 在骨生物学中的作用常常会产生相反的结果。这至少是部分由于一氧化氮合酶（NOS）的药理学抑制或遗传模型 NOS 缺乏症受到 NOS 异构体冗余的限制，不能解决细胞- NO 的自主角色。精氨基琥珀酸裂解酶（ASL），是尿素循环不仅需要的酶用于从头合成精氨酸（NOS 的底物），同时也维持结构含有 NOS、精氨基琥珀酸合酶 (ASS1)、精氨酸的 NO 合成复合物的完整性转运蛋白 CAT-1 和 HSP90。 ASL 的丧失会导致非冗余和细胞自主的丧失 NOS 依赖性 NO 产生，因此 ASL 缺陷 (ASLD) 是一种人类 NO 遗传性疾病生产。该提案的总体目标是研究 NO 在骨转换、密度和骨质疏松中的作用。人类一氧化氮缺乏模型中的结构，并了解其机制基础 NO影响骨代谢。通过利用这种罕见遗传疾病正在进行的试验，我们将解决这些具体问题：1) ASLD 患者是否存在骨转换异常？骨量以及不依赖 NOS 的 NO 补充剂是否会影响这些终点？ 2）做耐心- 衍生的诱导多能干细胞（iPSC）显示出沿成骨细胞的分化缺陷谱系以及这如何影响破骨细胞分化？ 3) 成骨细胞是否来自患者- 由于小窝蛋白依赖性阴性占主导地位，iPSC 表现出 NO 产生失调监管NOS复合体？这些研究可能会对骨生物学和骨生物学的基本理解产生重大影响。促进利用不依赖 NOS 的 NO 补充剂作为治疗方法的转化研究干预更常见的疾病，如骨质疏松症。